RE:RE:RE:RE:RE:RE:RE:AstraZeneca posts ADC wins at SABCS in breast cancerBoth ADCs and bispecific antibodies are increasingly seeking to be combined with immune checkpoint inhibitors which in turn can be enhanced beyond the 15-20% current effectiveness of the PD-(L)1 checkpoint inhibitors through the addition of oncolytic viruses specifically ONCY's pelareorep.
PD-(L)1 checkpoint inhibitors are negatively influenced by an immunosuppressive tumor microenvironment which pelareorep is able to overcome by down-regulating both HIF-1a and adenosine, responsible for tumor hypoxia and TME immunosuppression respectively.
So with ADCs or bispecific antibody therapy, the addition of immune checkpoint inhibitors with ONCY's pelareorep will ultimately be required for an enhanced combination I/O therapy benefit when sequentially administered together.